South Korea-based Lunit plans to highlight scientific findings related to its Lunit Scope Suite for precision oncology at the upcoming American Society of Clinical Oncology (ASCO) 2024 annual meeting in Chicago.
The studies include comprehensive histopathomic prediction models for early breast cancer and hypothetical test-and-control group generation for treatment selection in non-small cell lung cancer (NSCLC).
In the area of breast cancer, Lunit will present findings of recent HER2 studies, including ultra-low expression in breast cancer using AI-based quantification, and subcellular quantification from HER2 immunohistochemistry (IHC) images.
For NSCLC, Lunit will present findings from its deep learning-based model that integrates chest CT and histopathology analysis for predicting immunotherapy response, as well as its analysis of tertiary lymphoid structures in hematoxylin and eosin stain (H&E) whole-slide images to identify predictive biomarkers and predict immunotherapy response.
Toward precision oncology in skin cancer, a presentation will focus on a collaborative study that examined the association of immune phenotypes with outcomes after immunotherapy in metastatic melanoma, and it will highlight findings on the heterogeneity of immune phenotypes across melanoma subtypes, according to the firm.
